POH08 Updates in Supportive Oncodermatology
DESCRIPTION
This session will equip general dermatologists and oncodermatolgists with an updated overview of common and therapeutically challenging dermatologic adverse events (DAEs) associated with immune-checkpoint inhibitors (ICIs), EGFR inhibitors and bispecifics such as amivantamab. It will provide a practical approach on how to diagnose, classify and manage DAEs. It will summarize the latest insights into toxicity-specific pathogenesis and illustrate the rationale for using tailored, immune-based systemics to manage DAEs. Drawing from illustrative cases and preclinical/clinical studies, we will discuss the use of biologics (i.e. dupilumab, tocilizumab, IL-17i, IL-23i) to treat ICI-induced DAEs in cancer patients, with special emphasis on efficacy and safety.
LEARNING OBJECTIVES
Diagnose and manage dermatologic adverse events (DAEs) arising from systemic cancer treatments including immune-checkpoint inhibitors, EGFR inhibitors and the bispecific amivantimab.
Discuss updates in our current understanding of the pathophysiology and classification of specific mucocutaneous toxicities related to immunotherapy and chemotherapy.
Summarize and analyze the latest evidence for using biologics and immunomodulators to treat immune checkpoint inhibitor-related DAEs in cancer patients.
DIRECTOR
Sheila Shaigany, MD, FAAD
Northwell
SPEAKERS
Alexandra Coromilas, MD, FAAD
Columbia University Irving Medical Center
Nicholas David Gulati, MD, PhD, FAAD
DISCLOSURES
Alexandra Coromilas, MD, FAAD
No financial relationships exist with ineligible companies.
Nicholas David Gulati, MD, PhD, FAAD
Almirall – Advisory Board(Honoraria); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Daiichi Sankyo – Advisory Board(Honoraria); Veradermics – Advisory Board(Honoraria);
Sheila Shaigany, MD, FAAD
Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(No Compensation Received); Hoth Therapeutics – Investigator(No Compensation Received);